Synthesis and anti-cancer activity of chalcone linked imidazolones

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Chalcones and imidazolones are known pharmacophores with diverse biological activities.
• Developing novel anti-cancer agents is crucial for improving patient outcomes.
• Hybrid molecules can offer synergistic or enhanced therapeutic effects.

Purpose of the Study:

• To synthesize and characterize novel chalcone-linked imidazolone hybrids.
• To evaluate the anti-cancer activity of these compounds against a broad spectrum of human tumor cell lines.
• To investigate the mechanism of action, specifically the effect on cell cycle progression in breast cancer cells.

Main Methods:

• Chemical synthesis of chalcone-linked imidazolone derivatives.
• In vitro anti-cancer activity screening using a panel of 53 human tumor cell lines from nine cancer types.
• Cell cycle analysis using flow cytometry on MCF-7 breast carcinoma cells treated with selected compounds.

Main Results:

• Compounds 6, 7, and 8 exhibited potent anti-cancer activity, with GI(50) values between 1.26 and 13.9 microM.
• Treatment of MCF-7 cells with 10 microM of compounds TMAC, CA-4, 6, and 8 induced G2/M phase cell cycle arrest.
• A higher concentration (30 microM) of the same compounds led to cell accumulation in the G0/G1 phase, indicating a dose-dependent effect.

Conclusions:

• Chalcone-linked imidazolone hybrids represent a promising class of novel anti-cancer agents.
• The observed anti-cancer activity is associated with specific modulation of the cell cycle in cancer cells.
• Further investigation into these compounds could lead to the development of new therapeutic strategies for cancer treatment.